Ribonucleic acid (RNA) interference is a relatively new technique in which small molecules called short interfering RNA (siRNA) can be inserted into cells to turn off a chosen gene.

Sources Roberts, T.C et al. (2016) Synthetic SiRNA Delivery: Progress and Prospects Methods Mol Biol. 1364: pp. 291-310 [Accessed online 30 th April 2021] https://pubmed.ncbi.nlm.nih.gov/26472459 ...

Spotting this pathway as a potential chink in the armor of multiple myeloma, the team set out to design a small interfering RNA (siRNA)-based therapeutic to inhibit it and stop the cancer ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on technology to deliver siRNA molecules it discovered using its machine learning ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in ...

To get siRNA to organs beyond the liver, Alnylam has conjugated 2′-O-hexadecyl (C16) to the molecules. The C16 approach builds on a history of using lipophilic moieties to improve the delivery ...

siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...

The first siRNA drug, patisiran, was approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat a debilitating genetic disorder called hereditary transthyretin amyloidosis.

Sirius has also received approvals from the U.S. FDA and the China NMPA and has begun Phase 1 studies with SRSD216, a novel siRNA therapeutic for hyperlipoproteinemia in patients with ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...